Home/Pipeline/VIR-2218 + VIR-3434

VIR-2218 + VIR-3434

Chronic Hepatitis B (CHB)

Phase 2Active

Key Facts

Indication

Chronic Hepatitis B (CHB)

Phase

Phase 2

Status

Active

Company

Vir Biotechnology

About Vir Biotechnology

Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.

View full company profile

Therapeutic Areas

Infectious Diseases Oncology

Other Chronic Hepatitis B (CHB) Drugs

Drug	Company	Phase	Status
CARG-201	CaroGen	Pre-clinical	Active
Anti-HBVxCD3	Ancora Bio	Preclinical	Active
Pevifoscorvir sodium (ALG-000184)	Aligos Therapeutics	Phase 2	Active
ALG-125755	Aligos Therapeutics	Phase 1	Status Unclear (Deprioritized)